ArticleOncotarget2017
Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 99 citations in OpenAlex.
- Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation.Current allergy and asthma reports · 2026Review
- Case Report: aleukemic mast cell leukemia withFrontiers in oncology · 2026Article
- Impact of Molecular Evaluations in the Biology, Diagnosis, and Prognostication of Patients With Mastocytosis.The journal of allergy and clinical immunology. In practice · 2026Review
- Well-differentiated systemic mastocytosis: Genetics, mast cell immunophenotypes, and KIT autophosphorylation.The Journal of allergy and clinical immunology · 2025Article
- Mast Cell Leukemia: Comprehensive Review of Literature With Current Insights and Updates on Management.Journal of hematology · 2025Review
- The evaluation, management, and future of indolent systemic mastocytosis.Annals of hematology · 2025Review
- Clinical and Biological Characteristics of Four Patients with Aggressive Systemic Mastocytosis Treated with Midostaurin.Biomedicines · 2025Article
- Mastocytosis in the Skin: Approach to Diagnosis, Evaluation, and Management in Adult and Pediatric Patients.American journal of clinical dermatology · 2025Review
- Tumour-agnostic kinase inhibitors.Nature reviews. Drug discovery · 2025Review
- Systemic mastocytosis: current status and challenges in 2024.Blood advances · 2025Review
- A Rare Case of Acute Aleukemic Mast Cell Leukemia With Osteoblastic Lesions in the Appendicular Skeleton.Journal of hematology · 2025Article
- Utility of tryptase genotyping in the screening, diagnosis, and management of systemic mastocytosis.Frontiers in allergy · 2025Review
- Systemic Mastocytosis: State of the Art.Current hematologic malignancy reports · 2024Review
- [Two cases of systemic mastocytosis with RUNX1-RUNX1T1 positive acute myeloid leukemia treated with sequential avapritinib after allogeneic hematopoietic stem cell transplantation and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Review
- Poor Applicability of Currently Available Prognostic Scoring Systems for Prediction of Outcome inCancers · 2024Article
- Diffuse Cutaneous Mastocytosis: A Current Understanding of a Rare Disease.International journal of molecular sciences · 2024Review
- Recent Advances in the Therapeutic Management of Advanced Systemic Mastocytosis.Diagnostics (Basel, Switzerland) · 2023Review
- Mastocytosis demystified.Hematology. American Society of Hematology. Education Program · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to imatinib has been recurrently reported in systemic mastocytosis (SM) carrying exon 17
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.